AR045013A1 - Metodo para tratar o prevenir trastornos del sistema nervioso central con compuestos que tienen selectividad por la subunidad alfa -3 del receptor de benzodiazepinas - Google Patents
Metodo para tratar o prevenir trastornos del sistema nervioso central con compuestos que tienen selectividad por la subunidad alfa -3 del receptor de benzodiazepinasInfo
- Publication number
- AR045013A1 AR045013A1 ARP040102355A ARP040102355A AR045013A1 AR 045013 A1 AR045013 A1 AR 045013A1 AR P040102355 A ARP040102355 A AR P040102355A AR P040102355 A ARP040102355 A AR P040102355A AR 045013 A1 AR045013 A1 AR 045013A1
- Authority
- AR
- Argentina
- Prior art keywords
- nervous system
- central nervous
- disorders
- benzodiazepinas
- subunity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Uso de 1-ar(alqu)ilimidazolin-2-onas que contienen un radical amino disustituido en la posición 4, como por ejemplo el 1-(4-clorofenil)-4-piperidinoimidazolin-2-ona, entre otros, para el tratamiento o la prevención de trastornos del sistema nervioso central, incluyendo depresión, ansiedad, trastornos del movimiento y en especial distonía, y trastornos psicóticos, y especialmente esquizofrenia y síntomas psicóticos asociados a otros trastornos mentales. Composiciones farmacéuticas que los contienen.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48667803P | 2003-07-11 | 2003-07-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR045013A1 true AR045013A1 (es) | 2005-10-12 |
Family
ID=34062138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040102355A AR045013A1 (es) | 2003-07-11 | 2004-07-02 | Metodo para tratar o prevenir trastornos del sistema nervioso central con compuestos que tienen selectividad por la subunidad alfa -3 del receptor de benzodiazepinas |
Country Status (17)
Country | Link |
---|---|
US (2) | US20050032863A1 (es) |
EP (2) | EP1646386A2 (es) |
JP (1) | JP2009513539A (es) |
KR (1) | KR20060032633A (es) |
CN (2) | CN1822836A (es) |
AR (1) | AR045013A1 (es) |
AU (1) | AU2004255414A1 (es) |
BR (1) | BRPI0412512A (es) |
CA (1) | CA2531861A1 (es) |
MX (1) | MXPA05013196A (es) |
NO (1) | NO20060686L (es) |
NZ (1) | NZ544251A (es) |
RU (1) | RU2354377C2 (es) |
TW (1) | TW200512197A (es) |
UA (1) | UA87982C2 (es) |
WO (1) | WO2005004867A2 (es) |
ZA (1) | ZA200509169B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2008011216A (es) * | 2006-03-08 | 2008-09-11 | Hoffmann La Roche | 1,5-dihidro-imidazol-2-onas 4-amino-1,5-substituidas. |
US8779157B2 (en) | 2009-09-04 | 2014-07-15 | Vanderbilt University | MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
CN103796638A (zh) | 2011-08-12 | 2014-05-14 | 勃林格殷格翰动物保健有限公司 | 遮味药物组合物 |
CN104199105A (zh) * | 2014-08-27 | 2014-12-10 | 中国石油天然气集团公司 | 高密度三维勘探中初至的拾取方法及拾取装置 |
EP3482214A1 (en) * | 2016-07-11 | 2019-05-15 | Ranvier Health Limited | Method of diagnostic relevance based on taste recognition |
KR102489109B1 (ko) * | 2020-06-02 | 2023-01-16 | 부산대학교 산학협력단 | 아세틸콜린 수용체 변이 유전자를 유효성분으로 포함하는 근긴장 이상증 치료용 조성물 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI90869C (fi) * | 1986-11-14 | 1994-04-11 | Tanabe Seiyaku Co | Menetelmä lääkeaineena käyttökelpoisten imidatsolidinonijohdannaisten valmistamiseksi |
WO1997000931A1 (en) | 1995-06-23 | 1997-01-09 | Bausch & Lomb Incorporated | Method for cleaning contact lenses utilizing polysulfonates |
US5869481A (en) * | 1995-09-05 | 1999-02-09 | Arzneitmittelwerk Dresden G.M.B.H. | Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making |
DE19532668A1 (de) * | 1995-09-05 | 1997-03-06 | Dresden Arzneimittel | Neue, antikonvulsiv wirkende 1-Ar(alk)yl-imidazolin-2-one, die in 4-Stellung einen disubstituierten Amin-Rest enthalten, und Verfahren zu deren Herstellung |
US5861423A (en) * | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
DE19721580A1 (de) * | 1997-05-23 | 1998-11-26 | Dresden Arzneimittel | Verwendung von 1-Ar(alk)yl-imidazolin-2-one zur Behandlung von Angst- und Spannungszuständen |
WO1999037370A1 (en) | 1998-01-22 | 1999-07-29 | Precedence Publishing, Inc. | Game using collectibles as playing pieces |
GB9821179D0 (en) | 1998-09-30 | 1998-11-25 | Merck Sharp & Dohme | Therapeutic use |
GB9929687D0 (en) | 1999-12-15 | 2000-02-09 | Merck Sharp & Dohme | Therapeutic agents |
GB0018473D0 (en) | 2000-07-27 | 2000-09-13 | Merck Sharp & Dohme | Therapeutic agents |
GB0122696D0 (en) * | 2001-09-20 | 2001-11-14 | Merck Sharp & Dohme | Therapeutic agents |
US20050070537A1 (en) * | 2002-10-10 | 2005-03-31 | Chris Rundfeldt | Use of dihydroimidazolones for the treatment of dogs |
-
2004
- 2004-06-28 KR KR1020067000739A patent/KR20060032633A/ko not_active Application Discontinuation
- 2004-06-28 WO PCT/EP2004/006989 patent/WO2005004867A2/en active Application Filing
- 2004-06-28 CA CA002531861A patent/CA2531861A1/en not_active Abandoned
- 2004-06-28 US US10/878,987 patent/US20050032863A1/en not_active Abandoned
- 2004-06-28 CN CNA2004800199698A patent/CN1822836A/zh active Pending
- 2004-06-28 NZ NZ544251A patent/NZ544251A/en unknown
- 2004-06-28 RU RU2006104118/14A patent/RU2354377C2/ru not_active IP Right Cessation
- 2004-06-28 UA UAA200600251A patent/UA87982C2/ru unknown
- 2004-06-28 MX MXPA05013196A patent/MXPA05013196A/es unknown
- 2004-06-28 BR BRPI0412512-6A patent/BRPI0412512A/pt not_active IP Right Cessation
- 2004-06-28 JP JP2006519793A patent/JP2009513539A/ja not_active Withdrawn
- 2004-06-28 AU AU2004255414A patent/AU2004255414A1/en not_active Abandoned
- 2004-06-28 EP EP04740387A patent/EP1646386A2/en not_active Withdrawn
- 2004-06-28 CN CNA200710169458XA patent/CN101254189A/zh active Pending
- 2004-06-28 EP EP08168609A patent/EP2027856A1/en not_active Withdrawn
- 2004-06-29 TW TW093119215A patent/TW200512197A/zh unknown
- 2004-07-02 AR ARP040102355A patent/AR045013A1/es unknown
-
2005
- 2005-11-14 ZA ZA200509169A patent/ZA200509169B/xx unknown
-
2006
- 2006-02-13 NO NO20060686A patent/NO20060686L/no not_active Application Discontinuation
-
2007
- 2007-10-29 US US11/978,362 patent/US20080114032A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BRPI0412512A (pt) | 2006-09-19 |
RU2006104118A (ru) | 2006-06-10 |
EP1646386A2 (en) | 2006-04-19 |
MXPA05013196A (es) | 2006-03-09 |
AU2004255414A1 (en) | 2005-01-20 |
UA87982C2 (ru) | 2009-09-10 |
NZ544251A (en) | 2009-12-24 |
WO2005004867A3 (en) | 2005-04-21 |
TW200512197A (en) | 2005-04-01 |
CN101254189A (zh) | 2008-09-03 |
WO2005004867A2 (en) | 2005-01-20 |
JP2009513539A (ja) | 2009-04-02 |
RU2354377C2 (ru) | 2009-05-10 |
NO20060686L (no) | 2006-03-14 |
EP2027856A1 (en) | 2009-02-25 |
CN1822836A (zh) | 2006-08-23 |
KR20060032633A (ko) | 2006-04-17 |
CA2531861A1 (en) | 2005-01-20 |
US20050032863A1 (en) | 2005-02-10 |
US20080114032A1 (en) | 2008-05-15 |
ZA200509169B (en) | 2006-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT200600165A (es) | Derivados dihidrobenzofuranos y usos de los mismos | |
ECSP067021A (es) | Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar) | |
PA8675701A1 (es) | Nuevos derivados del fluoreno, composiciones que los contienen y su utilización | |
ECSP055535A (es) | Derivados de 1-heterociclialquil-3-sulfonilazaindol o azaindol como ligandos de 5-hidroxitriptamina-6 | |
UY29796A1 (es) | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor | |
ECSP10010034A (es) | 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos | |
ECSP055536A (es) | Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6 | |
ECSP067019A (es) | Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar) | |
HN2004000319A (es) | "{ 1,8}naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia" | |
GT200600161A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos | |
AR047841A1 (es) | Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios | |
UY31748A (es) | Nuevos compuestos para el tratamiento de trastornos del snc (sistema nervioso central) | |
ECSP077421A (es) | Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1 | |
CL2008002793A1 (es) | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras | |
UY27976A1 (es) | Piperazinas heterocíclicas sustituídas para el tratamiento de la esquizofrenia | |
UY28876A1 (es) | Compuestos de morfolina sustituida y composiciones para el tratamiento de trastornos del sistema nervioso central | |
ECSP045474A (es) | 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6 | |
CR10309A (es) | "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1" | |
CL2004000849A1 (es) | Compuestos derivados de benzamidas-2-hidroxi-3-diaminoalcanos, utiles para el tratamiento o la prevencion de alzheimer, sindrome de down, hemorragia cerebral hereditaria, demencias degenerativas y otras. | |
AR054347A1 (es) | Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
CL2008002162A1 (es) | Compuestos derivados de 3-benzoisoxazol-piperidin; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento y/o prevencion de trastornos cognitivos, adiccion a drogas, depresion, ansiedad, entre otras. | |
DOP2010000062A (es) | Derivados de ciclopropilamida | |
ECSP088366A (es) | 1,2-diarilimidazoles para uso como moduladores de cb1 | |
GT200500332A (es) | Azabenzoxazoles para el tratamiento de trastornos del snc | |
GT200600130A (es) | Tetrahidropiridoazepin-8-onas y compuestos relacionados para el tratamiento de la esquizofrenia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |